MetaVia Inc. (MTVA) shares climbed during Friday's premarket session after the company announced it's built a comprehensive intellectual property fortress around its lead obesity drug candidate.
The biotech revealed it now holds 39 granted and pending patents across the U.S. and international markets for DA-1726, a treatment designed to tackle obesity and related metabolic disorders. That protection runs through 2041 unless extended further, giving the company more than a decade and a half of exclusivity to work with.
DA-1726 works as a dual GLP-1/glucagon agonist, which CEO Hyung Heon Kim highlighted as the drug's unique design feature that the patent portfolio protects. Recent clinical results back up the promise: patients taking the 48 mg dose saw 9% weight loss, along with notable improvements in waist circumference and blood sugar control.
The Technical Picture Looks Rough
Friday's rally is a bright spot in what's otherwise been a brutal stretch for MetaVia. The stock sits 21.8% below its 20-day simple moving average and a staggering 77.6% below its 200-day average. Over the past year, shares have cratered 90.85%, trading much closer to 52-week lows than highs.
But there are some silver linings in the technical indicators. The RSI sits at 23.34, firmly in oversold territory, suggesting the stock might be due for a bounce. The MACD has also crossed above its signal line, hinting at potential bullish momentum even as the broader trend remains bearish. That combination of oversold conditions and emerging positive signals could point to a near-term reversal.
Key levels to watch: resistance at $2.00 and support at $1.50.
Bucking the Healthcare Sector Trend
MetaVia's roughly 10% gain Friday stands out sharply against the Healthcare sector's modest 0.17% uptick. The sector itself ranks fifth out of eleven, showing mid-tier performance overall. Over the past month, Healthcare has slipped 1.18%, though it's up 2.83% over the trailing 90 days. MetaVia's Friday performance represents a significant divergence from those sector trends.
What the Analysts Think
The stock carries a Buy rating from analysts. HC Wainwright & Co. maintains a Buy rating and recently raised its price target to $40.00 on January 6th. That target implies massive upside from current levels.
Price Action: MetaVia shares were trading up 9.64% at $1.84 at the time of publication Friday. The stock hovers just above its 52-week low of $1.61.
